HST-1011

Phase 2Small molecule

HHotSpot Therapeutics, Inc

HST-1011 is one of 7 small molecule programs targeting PD-1antibody. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pd-1antibodyActive, not recruiting

Pd-1antibodyPhase 2

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Pd-1antibody

#DrugCompanyPhaseTrials

Kuvan

BioMarin Pharmaceutical

Phase 2

1 2

Libtayo

Regeneron

Phase 2

1 3

Opzelura

DDizal Pharmaceuticals

Phase 2

1 4

PD-1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 2

10 5

Chidamide

CChipscreen Biosciences, Ltd.

Phase 2

1 6

L-DEP and PD-1 Antibody

BBeijing Friendship Hospital

Phase 3

2 7

HST-1011

HHotSpot Therapeutics, Inc

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Active, not recruiting

Pd-1antibody

NCT05662397

Clinical

Trials by Indication[1]

PD-1antibody1 trial

A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody

Active, not recruiting·HHotSpot Therapeutics, Inc·Phase 1/2·NCT05662397·77 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HST-1011. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HST-1011 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HST-1011. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — HotSpot Therapeutics, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHotSpot Therapeutics, Inc

HST-1011

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

PD-1antibody1 trial

References

Drug Info

Quick Facts

Related News